CRC Research Update — October 07, 2026
Today's colorectal cancer research highlights
kras
A collection of 116 issues
ENOPH1 identified as key mediator of KRAS G12D/G13D-driven metabolic reprogramming
Skip to content
The CRC Digest
◇ RESEARCH
ENOPH1 identified as key mediator of KRAS G12D/G13D-driven metabolic reprogramming
Preclinical research shows ENOPH1 is upregulated by the KRAS-MEK-ERK pathway and sustains oncogenic TGF-β/SMAD signaling, representing a potential therapeutic target in KRAS-mutant colorectal cancer. (International Immunopharmacology)
This content is informational only
CRC Research Update — October 05, 2026
Today's colorectal cancer research highlights
Danish cohort study examines KRAS mutation status and VTE risk in colorectal cancer
Skip to content
The CRC Digest
◇ RESEARCH
Danish cohort study examines KRAS mutation status and VTE risk in colorectal cancer
A population-based cohort study of Danish patients with stage I-IV colorectal cancer who underwent KRAS mutation testing between 2015 and 2023 examined the association between KRAS mutation status and 1-year
RTK-RAS pathway alterations show age-dependent clinical significance in colorectal cancer
Skip to content
The CRC Digest
◇ RESEARCH
RTK-RAS pathway alterations show age-dependent clinical significance in colorectal cancer
RTK-RAS alterations have been associated with unfavorable survival in untreated early-onset non-Hispanic White colorectal cancer, while an opposite association has been observed in FOLFOX-treated late-onset disease. (Journal of Cancer Biology)
This content is
Phase II trial compares sequencing of regorafenib and anti-EGFR therapy in refractory metastatic colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase II trial compares sequencing of regorafenib and anti-EGFR therapy in refractory metastatic colorectal cancer
The REVERCE II trial randomized patients with RAS wild-type metastatic colorectal cancer to receive either regorafenib followed by anti-EGFR therapy or the reverse sequence, evaluating overall survival
CRC Research Update — October 03, 2026
Today's colorectal cancer research highlights
Early-onset CRC shows distinct genomic landscape in dual-cohort analysis
Skip to content
The CRC Digest
◇ RESEARCH
Early-onset CRC shows distinct genomic landscape in dual-cohort analysis
Analysis of TCGA PanCancer Atlas and MSK-IMPACT 50K cohorts reveals reproducible mutational differences in colorectal cancer diagnosed before age 50, with implications for biomarker-driven treatment. (PLoS One)
This content is informational only and does
CRC Research Update — October 02, 2026
Today's colorectal cancer research highlights
CRC Research Update — October 01, 2026
Today's colorectal cancer research highlights